On the morning of March 14, 2023, Hu Jianwei, Vice President of Sinopharm Group (in charge of operations), and Vice President Deng Jindong visited Maxin Biotech for research and guidance. Liang Hongjun, Party Secretary and Chairman of Sinopharm Investment, accompanied the visit.。
Hu Jianwei and his delegation conducted an on-site inspection of Maxin Biotech’s exhibition hall, quality inspection laboratory, and production workshop. They gained a detailed understanding of the company’s product structure, quality control system, and production system construction. They fully recognized the development achievements of the company and highly praised its active commitment to social responsibility.
During the symposium, the person in charge of Maxin Biotech comprehensively introduced the company’s production and operation, market sales, industrial layout, and future development plans. Hu Jianwei pointed out that the pharmaceutical and health industry has broad development prospects. As a leading enterprise in China’s pathological diagnosis industry, Maxin Biotech should actively integrate into Sinopharm Group’s overall development strategy of ‘Four Pillars and Eight Beams, Hundred Strong and Trillion Scale’, seize opportunities, strive for success, consolidate advantages, and make contributions in implementing the ‘Healthy China’ strategy. He emphasized that Maxin Biotech should earnestly study Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, implement the spirit of the 20th National Congress of the Communist Party of China. Firstly, vigorously promote the spirit of entrepreneurship, actively leverage the value of entrepreneurs, and promote the company’s high-quality development. Secondly, firmly grasp the innovation-driven development strategy, rely on technological and institutional innovation, and comprehensively enhance the core competitiveness of the enterprise. Thirdly, intensify efforts to advance organizational reform, actively recognize, adapt to, and seek changes, proactively adapt to new situations and changes, and ensure the healthy and sound development of the enterprise. During the symposium, Deng Jindong stated that Maxin Biotech should accelerate the pace of technological innovation, strengthen talent team building, and focus on diversified product layout. Through the dual-drive of ‘endogenous growth and external expansion’, the company should maintain long-term effective growth and achieve high-quality development.
Wang Xiaoya, General Manager of Maxin Biotech, Lin Qixin, Deputy General Manager of Operations, Wang Jianmin, Deputy General Manager, and Yang Qinghai, Deputy General Manager, participated in the research and symposium.
